VRTX Jun 2025 540.000 call
| Previous close | 20.45 |
| Open | 20.45 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 540.00 |
| Expiry date | 2025-06-20 |
| Day's range | 20.45 - 20.45 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksVertex Pharmaceuticals (VRTX) Surpasses Market Returns: Some Facts Worth Knowing
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $465.08, denoting a +0.48% change from the preceding trading day.
ZacksWall Street Analysts See Vertex (VRTX) as a Buy: Should You Invest?
The average brokerage recommendation (ABR) for Vertex (VRTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Business WireVertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference
BOSTON, September 26, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the first accepted medical presentations of the Phase 3 data on the investigational once daily vanzacaftor/tezacaftor/deutivacaftor ("vanza triple") — the potential next-in-class triple combination medicine — will take place at the North American Cystic Fibrosis Conference (NACFC). Vertex also announced presentations describing long-term outcomes in people with cystic fibrosis (CF) ages 2 to 11 years t
